S.A.T. 60c

S.A.T. by Thorne contains milk thistle which offers strong antioxidants that protect liver cells from damage, help maintain the built in antioxidant system of the liver, and strengthen the membranes of liver cells. Silymarin, the active ingredient in milk thistle, helps maintain the body’s inflammatory response and can protect the liver from harmful chemicals such as acetaminophen, benzopyrene, ethanol, mushroom toxins, and carbon tetrachloride. Siliphos, an ingredient in S.A.T., combines silybin (the most abundant component of silymarin) with phosphatidylcholine to promote absorption. Another ingredient in this product is artichoke (Cynara scolymus), which also supports the liver. Curcumin (from turmeric) is also present in S.A.T. and has strong antioxidant characteristics. It also supports the body’s natural inflammatory response. Curcumin is in the form of Meriva (curcumin bound to phosphatidylcholine), which has an increased absorption profile over traditional curcumin.*

 

Thorne suggests taking 1 S.A.T. capsule two to three times per day, or as directed by a healthcare provider. 

 

Serving Size: 1 Vegetarian Capsule

Servings per Container: 60

Silybin Phytosome* (Silybum marianum extract (fruit) / Phosphatidylcholine complex) 150 mg

Artichoke extract (leaf) (Cynara scolymus) 150 mg.

Curcumin Phytosome* (Curcuma longa extract (root) / Phosphatidylcholine complex) 150 mg.

Microcrystalline Cellulose, Hypromellose (derived from cellulose) capsule, Leucine, Silicon Dioxide.

 

This Thorne product contains ingredients derived from soy. 

 

Curcumin has been shown to reduce the therapeutic efficacy of cyclophosphamide (Cytoxan) in animal studies. In vitro research reveals curcumin decreased camptothecin-induced death of cultured breast cancer cells. Curcumin might also interfere with the absorption and efficacy of the chemotherapy drug irinotecan, used to treat colon cancer. The concurrent use of curcumin with these agents should be avoided.